Global Single‑Use Bioreactors Market Outlook

The global single-use bioreactors market size was valued at USD 4.42 billion in 2024. The market is projected to grow from USD 4.81 billion in 2025 to USD 10.42 billion by 2034, exhibiting a CAGR of 9.0% during 2025–2034.

representing a compound annual growth rate (CAGR) of about 15%. Single‑use bioreactors replace traditional stainless‑steel vessels with disposable bags and assemblies, enabling rapid changeovers, reduced cleaning requirements, and lower capital and operating expenditures. This technology is gaining traction across small‑ and mid‑scale biologics manufacturing, contract development and manufacturing organizations (CDMOs), and research and development operations.

Market Overview

The single‑use bioreactor market is part of the broader biologics and cell/process‑development manufacturing sector. The growth of biologics, biosimilars, gene‑ and cell‑therapies, and vaccine manufacturing has created increasing demand for flexible, cost‑efficient upstream manufacturing solutions. Single‑use bioreactors reduce turnaround time, lower risk of contamination, and require less infrastructure investment compared to traditional stainless steel systems.

Market segmentation includes product types (bioreactor systems, media bags/assemblies, consumables), bioreactor type (stirred‑tank, wave‑induced, bubble‑column), cell type (mammalian, microbial, yeast), molecule/application (monoclonal antibodies, vaccines, gene‑modified cells), end‑user (pharma/biotech, CDMOs/CROs, academic/research), and region. The “systems” segment, including full single‑use bioreactor setups, holds a significant share of the market, while stirred‑tank configurations dominate due to their high oxygen transfer and mixing performance.

Key Market Growth Drivers

1. Rising biologics and biosimilars production – Increasing development of monoclonal antibodies, recombinant proteins, vaccines, and cell & gene therapies fuels demand for upstream processing capacity. Single‑use solutions enable faster deployment and scale‑up compared to traditional equipment.
2. Adoption by CDMOs and small/mid‑sized biotechs – Outsourcing of manufacturing and the need for flexible capacity favor single‑use technologies that reduce initial capital investment and facility footprint.
3. Reduced capital expenditure and faster turnaround – Single‑use systems reduce or eliminate cleaning/sterilization requirements, enable quicker changeovers, and support multi-product facilities and flexible manufacturing strategies.
4. Resource efficiency and sustainability benefits – Compared to stainless steel bioreactors, single‑use solutions decrease water and energy consumption, reduce cleaning and validation time, and lower contamination risk.

Market Challenges

1. Extractables & leachables and material concerns – The use of disposable plastics introduces issues around sterility assurance, extractables/leachables, material compatibility, and regulatory acceptance.
2. Scale‑up and performance limitations – Single‑use bioreactors may underperform compared to large-scale stainless steel vessels in oxygen transfer, agitation, and shear, which limits their use in high-volume production.
3. Regulatory and validation requirements – Single-use systems require rigorous qualification and documentation, adding cost and complexity for pharmaceutical manufacturing.
4. Waste management and sustainability concerns – While single-use systems reduce cleaning-related resource usage, their disposable nature generates additional waste streams, raising environmental considerations.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/single-use-bioreactors-market

Regional Analysis

• North America is the largest regional market, benefiting from a strong biopharma ecosystem, established CDMO infrastructure, and regulatory maturity.
• Europe is the second-largest market, driven by biosimilars, biologics approvals, and robust life-science infrastructure in key countries.
• Asia-Pacific is expected to grow the fastest, with emerging markets such as China, India, South Korea, and Singapore expanding biologics manufacturing capacity and adopting single-use technologies.
• Latin America and Middle East & Africa are smaller markets but present growth potential due to rising healthcare expenditure, regulatory maturation, and investments in biotechnology hubs.

Key Companies in the Single-Use Bioreactors Market

• Thermo Fisher Scientific
• Sartorius AG
• Eppendorf AG
• Merck KGaA
• GE Healthcare
• Danaher Corporation
• Pall Corporation
• Repligen Corporation
• Lonza Group
• ABEC
• Applikon Biotechnology
• Celltech Pharma
• Fujifilm Irvine Scientific
• Hamilton Company
• Saint-Gobain

Conclusion

The Single-Use Bioreactors market is at a dynamic phase of growth, driven by biologics, vaccine, and cell/gene-therapy manufacturing, as well as the trend toward flexible, cost-efficient infrastructure. Market size is expected to at least double over the next five years, with strong opportunities continuing into the early 2030s.

However, stakeholders must address challenges related to technical performance, regulatory requirements, material science issues, and waste management. Success will favor companies offering validated, high-performing, and scalable solutions, alongside automation, monitoring, and lifecycle support.

More Trending Latest Reports By Polaris Market Research:

Buy Now Pay Later Market

Wafer Vacuum Assembling Equipment Market

Biorational Market

Cell & Gene Therapy Bioanalytical Testing Services Market

Wafer Vacuum Assembling Equipment Market

Specialty Food Ingredients Market

Virus Filtration Market

Unveiling the Buzzing World of Insecticides Market

Activated Carbon Market

Security Inks Market

IT Services Market

Edible Oils & Fat Market

Cell & Gene Therapy Bioanalytical Testing Services Market